NovoCure Limited (NASDAQ:NVCR) CTO Yoram Palti sold 30,000 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $18.25, for a total value of $547,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Yoram Palti also recently made the following trade(s):
- On Tuesday, November 7th, Yoram Palti sold 60,000 shares of NovoCure Limited stock. The stock was sold at an average price of $21.06, for a total value of $1,263,600.00.
- On Thursday, November 2nd, Yoram Palti sold 30,000 shares of NovoCure Limited stock. The stock was sold at an average price of $21.78, for a total value of $653,400.00.
NovoCure Limited (NASDAQ NVCR) opened at $17.05 on Tuesday. NovoCure Limited has a twelve month low of $6.00 and a twelve month high of $22.30. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.30 and a current ratio of 5.90.
NovoCure Limited (NASDAQ:NVCR) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.07. NovoCure Limited had a negative return on equity of 57.68% and a negative net margin of 47.45%. The company had revenue of $50.10 million for the quarter, compared to analysts’ expectations of $43.45 million. During the same period last year, the business earned ($0.39) EPS. NovoCure Limited’s quarterly revenue was up 130.9% compared to the same quarter last year. equities research analysts anticipate that NovoCure Limited will post -0.63 EPS for the current year.
NVCR has been the topic of a number of research analyst reports. Deutsche Bank AG restated a “hold” rating and set a $19.00 price target (up from $18.00) on shares of NovoCure Limited in a report on Monday, July 17th. BidaskClub cut NovoCure Limited from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research cut NovoCure Limited from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Mizuho began coverage on NovoCure Limited in a report on Wednesday, September 6th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $25.00 target price (down from $29.00) on shares of NovoCure Limited in a report on Friday, October 27th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. NovoCure Limited currently has a consensus rating of “Buy” and a consensus price target of $21.00.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pier Capital LLC purchased a new stake in NovoCure Limited in the 3rd quarter valued at $5,426,000. Stifel Financial Corp purchased a new stake in NovoCure Limited in the 3rd quarter valued at $1,778,000. Wells Fargo & Company MN raised its position in NovoCure Limited by 44.8% in the 3rd quarter. Wells Fargo & Company MN now owns 66,058 shares of the medical equipment provider’s stock valued at $1,312,000 after buying an additional 20,439 shares during the last quarter. Trexquant Investment LP purchased a new stake in NovoCure Limited in the 3rd quarter valued at $212,000. Finally, Legal & General Group Plc raised its position in NovoCure Limited by 80.6% in the 3rd quarter. Legal & General Group Plc now owns 25,045 shares of the medical equipment provider’s stock valued at $502,000 after buying an additional 11,179 shares during the last quarter. 36.21% of the stock is owned by institutional investors and hedge funds.
NovoCure Limited Company Profile
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.